DOCSLIB.ORG

US 2009/0252816A1 Abraini Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2009/0252816A1 Abraini Et Al US 2009025281 6A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0252816A1 Abraini et al. (43) Pub. Date: Oct. 8, 2009 (54) NHAILABLE GASEOUSMEDICAMENT (30) Foreign Application Priority Data BASED ON XENON AND NITROUS OXDE Jul. 30, 2003 (FR) ....................................... O350383 (75) Inventors: Jacques Abraini, Caen (FR); Marc Lemaire, Paris (FR) Publication Classification Correspondence Address: (51) Int. Cl. AIR LIQUIDE A633/00 (2006.01) Intellectual Property (52) U.S. Cl. ........................................................ 424/718 2700 POST OAKBOULEVARD, SUITE 1800 HOUSTON, TX 77.056 (US) (57) ABSTRACT (73) Assignee: AIR LIQUIDE SANTE The invention concerns the use of a gaseous mixture contain (INRTERNATIONAL), Paris (FR) ing gas Xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for (21) Appl. No.: 12/417,087 preventing or treating neurointoxication in a human. The Xenon/nitrous oxide mixture of the invention acts on one or (22) Filed: Apr. 2, 2009 more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, Related U.S. Application Data noradrenaline and/or any other neurotransmitter. The propor (62) Division of application No. 10/563,278, filed on Oct. tion by volume of xenon of the mixture ranges between 5 and 6, 2006, filed as application No. PCT/FR2004/050352 45%, and the proportion by Volume of nitrous oxide ranges on Jul. 23, 2004. between 10 and 50%, the balance is preferably oxygen. Patent Application Publication Oct. 8, 2009 Sheet 1 of 3 US 2009/025281.6 A1 4OO >- - -- r" " - - ----...--. is 200 - r --- C) s O os T O C) O - - s SH r 7 |7 || 7 |7 AR. N2007. NC 757. Petreatment saline amph satine aniel Safarig" Challenge Salamhsalanph salamphsalamph Salai Eph Satangh * P40,05 FG. Patent Application Publication Oct. 8, 2009 Sheet 2 of 3 US 2009/025281.6 A1 1400 +----------- >s 1200 ------------ - - - - - rs1-------------------------. a. 600. 8 go | | | | | | | 2CO - || || 2 O els Itlast Isle88 als 8 re? R. Xe 50 5. Pretreatment satine anph saline amph saline art ph Challenge Salamphsala?iph Salamisalarnph Salamhsalamph - P.C. C. OS FG, 2 water Patent Application Publication Oct. 8, 2009 Sheet 3 of 3 US 2009/025281.6 A1 F-89:28 lessefixeig: SAEEE S.A., Avi Pi AMPH 75% NO US 2009/025281.6 A1 Oct. 8, 2009 NHAILABLE GASEOUSMEDICAMENT underlines the rapid and long-lasting psychotropic analgesic BASED ON XENON AND NITROUS OXDE effects of nitrous oxide in the mechanism of weaning from alcohol. CROSS REFERENCE TO RELATED (0011. In Postgrad. Med. J. Clinical Toxicology, 1990, 66, APPLICATION pp. 543-546, the same authors explain that the nitrous oxide concentrations may vary from less than 15% to more than 0001. This present application is a divisional of U.S. 70% depending on the individual, as a function of his or her patent application Ser. No. 10/563.278 which has a U.S. filing degree of alcohol dependency. date of Oct. 6, 2006 and which is a S371 of International PCT 0012 Moreover, document EP-A-1 158992 teaches the Application PCT/FR2004/050352, filed Jul. 23, 2004. use of Xenon or of a mixture of Xenon with oxygen, nitrogen or air to treat neurointoxications. However, the use of Xenon FIELD OF INVENTION or of the mixtures described by said document is not entirely 0002 The invention relates to the use of a gaseous mixture satisfactory in practice, especially due to the appearance of containing Xenon and nitrous oxide (N2O) to manufacture all toxicity for certain Xenon contents and given the high cost of or part of an inhalable medicament for treating or preventing this compound. a pathology with a neurotoxic effect, i.e. neurointoxication, 0013 Moreover, U.S. Pat. No. 6,274,633 teaches the use especially the neurotoxic effects of drugs or other addictive of Xenon as an NMDA receptor antagonist compound Substances. assumed to be involved in neurotoxicity and neuronal cell death caused by certain diseases or ischemic hypoxia or fol BACKGROUND lowing a heart attack, in particular. 0014. In addition, EP-A-861 672 proposes inhalable gas 0003. In pathologies associated with the neurotoxic eous mixtures based on oxygen and on several possible gases, effects of addictive drugs, such as amphetamines, it is including Xenon. accepted that dopaminergic neurotransmission of nigrostri 0015 Finally, FR-A-2596989 proposes gaseous mixtures atal and mesolimbic origin participates in the psychoStimu based on nitrous oxide and oxygen, which may possibly lant and neurotoxic effects of these drugs. contain Xenon or other gases, as radiosensitizing products, 0004. However, recent studies by Del Arco et al., Neurop which may especially be used in cancer radiotherapy. harmacology, 38: 943, 1999, have shown that the facilitating 0016. The present invention falls within this context and is effects of amphetamines are not limited to dopaminergic neu directed toward improving the existing inhalable medica rotransmission. ments intended for effectively preventing or treating a state of 0005 Thus, in the striatum-nucleus accumbens septicom addiction in humans, i.e. any condition, disorder or pathology plex, amphetamines induce not only an increase in dopamine associated with neurotoxic effects, in particular the neuro release but also an increase in serotonin, taurine, Y-aminobu toxic effects of addictive drugs. tyric acid (GABA) and glutamate release. 0006. It has been shown, particularly advantageously, that SUMMARY OF THE INVENTION the specific inhibition of glutamate transporters makes it pos sible to reduce both hyperactivity (David, Thévenoux and 0017. The solution of the invention thus relates to the use Abraini, Neuropharmacology, 2001) and the increase in of a gaseous mixture containing Xenon (Xe) gas and nitrous glutamate, but not in dopamine (Del Arco et al., Neurophar oxide (NO) gas to manufacture all or part of an inhalable macology 38: 943, 1999), following injection of amphet medicament for preventing or treating a neurointoxication in amines, thus suggesting a decisive role of glutamate in the man, the volume proportion of xenon being between 5% and psychostimulant effects of amphetamines. 45% and the volume proportion of nitrous oxide being 0007 Moreover, recent studies, performed in vitro, have between 10% and 50%. shown that xenon and nitrous oxide (N2O) can behave like antagonists with low affinity for the N-methyl-D-aspartate BRIEF DESCRIPTION OF THE FIGURES glutamatergic receptors (NMDA: Franks et al., Nature 396: 0018 FIG. 1 illustrates the effects of nitrous oxide at 50 324, 1998; Jevtovic-Todorovic et al; Nature Med. 4: 460, vol % and 75 vol % (with the remainder of oxygen) on 1998). sensitization to d-amphetamine. 0008. In addition, in the context of the study of the endog 0019 FIG. 2 illustrates the effects of xenon at 50% and enous hyperalgesic opioid system in the negative placebo 75% on sensitization to d-amphetamine. response, F. J. Lichtigfeld and M. A. Gillman, Intern. J. Neu 0020 FIG. 3 illustrates the effects of nitrous oxide on the roscience, 1989, Vol. 49, pp.71-74 conclude that the effect of increase in dopamine release in the nucleus accumbens septi nitrous oxide on weaning from alcohol is slightly better than induced with d-amphetamine. the placebo effect, although, for more than 50% of the indi viduals, an identical positive effect was also found with the placebo. DETAILED DESCRIPTION OF THE INVENTION 0009. However, the same authors add, in Nitrous Oxide 0021. The present invention relates to the use of a gaseous and the Aws, p. 785, that the beneficial effect of nitrous oxide mixture containing Xenon gas and nitrous oxide gas in order depends closely on its concentration, since anesthetic or pre to manufacture all or part of an inhalable medicament for anesthetic concentrations are ineffective, or are even counter preventing or treating neurointoxication in man. productive in certain cases, an analgesic concentration being 0022 Depending on the case, the use of the invention may recommended. include one or more of the following technical characteristics: 0010 Yet another publication from these authors, pub 0023 the neurointoxication results from a cerebral lished in Intern. J. Neuroscience, 1994, Vol. 76, pp. 17-33, excess of one or more neurotransmitters, US 2009/025281.6 A1 Oct. 8, 2009 0024 the mixture containing xenon and nitrous oxide and derivatives thereof, cocaine, tobacco, alcohol, cannabis acts on at least one cerebral receptor so as to reduce the or any other dependency-generating Substance, especially all effects and/or the release of dopamine, glutamate, sero or part of an inhalable gaseous medicament. tonin, taurine, GABA, noradrenalin and/or any other 0038. In general, the medicament according to the inven neurotransmitter, tion may be administered to the patient via his upper respira 0025 the volume proportion of xenon is between 20% tory pathways, i.e. by inhalation via the nose and/or the and 40% and the Volume proportion of nitrous oxide is mouth, using a suitable administration device comprising a between 10% and 40%, patient respiratory interface, such as a respiratory mask or 0026 the volume proportion of xenon is between 20% tracheal probe, one or more feed pipes serving to convey the and 32% and the Volume proportion of nitrous oxide is gaseous medicament from a source containing said medica between 20% and 40%, and preferably the volume pro ment to the interface, and a medical ventilator serving to portions of Xenon and of
Load more

Recommended publications
  • EL PASO INTELLIGENCE CENTER DRUG TREND Synthetic Stimulants Marketed As Bath Salts
    LAW ENFORCEMENT SENSITIVE EPIC Tactical Intelligence Bulletins EL PASO INTELLIGENCE CENTER DRUG TREND TACTICAL INTELLIGENCE BULLETIN EB11-16 ● Synthetic Stimulants Marketed as Bath Salts ● March 8, 2011 This document is the property of the Drug Enforcement Administration (DEA) and is marked Law Enforcement Sensitive (LES). Further dissemination of this document is strictly forbidden except to other law enforcement agencies for criminal law enforcement purposes. The following information must be handled and protected accordingly. Summary Across the United States, synthetic stimulants that are sold as “bath salts”¹ have become a serious drug abuse threat. These products are produced under a variety of faux brand names, and they are indirectly marketed as legal alternatives to cocaine, amphetamine, and Ecstasy (MDMA or 3,4-Methylenedioxymethamphetamine). Poison control centers nationwide have received hundreds of calls related to the side-effects of, and overdoses from, the use of these potent and unpredictable products. Numerous media reports have cited bath salt stimulant overdose incidents that have resulted in emergency room visits, hospitalizations, and severe psychotic episodes, some of which, have led to violent outbursts, self-inflicted wounds, and even suicides. A number of states have imposed emergency measures to ban bath salt stimulant products (or the chemicals in them) including Florida, Louisiana, North Dakota, and West Virginia; and similar measures are pending in Hawaii, Kentucky, Michigan, and Mississippi. A prominent U.S.
    [Show full text]
  • Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release
    Neuropsychopharmacology (2003) 28, 34–44 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release Andrea Balla1, Henry Sershen1,2, Michael Serra1, Rajeth Koneru1 and Daniel C Javitt*,1,2 1 2 Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; Department of Psychiatry, New York University School of Medicine, New York, NY, USA Functional dopaminergic hyperactivity is a key feature of schizophrenia. Etiology of this dopaminergic hyperactivity, however, is unknown. We have recently demonstrated that subchronic phencyclidine (PCP) treatment in rodents induces striatal dopaminergic hyperactivity similar to that observed in schizophrenia. The present study investigates the ability of PCP to potentiate amphetamine-induced dopamine release in prefrontal cortex (PFC) and nucleus accumbens (NAc) shell. Prefrontal dopaminergic hyperactivity is postulated to underlie cognitive dysfunction in schizophrenia. In contrast, the degree of NAc involvement is unknown and recent studies have suggested that PCP-induced hyperactivity in rodents may correlate with PFC, rather than NAc, dopamine levels. Rats were treated with 5–20 mg/kg/day PCP for 3–14 days by osmotic minipump. PFC and NAc dopamine release to amphetamine challenge (1 mg/kg) was monitored by in vivo microdialysis and HPLC-EC. Doses of 10 mg/kg/day and above produced serum PCP concentrations (50–150 ng/ml) most associated with PCP psychosis in humans. PCP-treated rats showed significant, dose-dependent enhancement in amphetamine-induced dopamine release in PFC but not NAc, along with significantly enhanced locomotor activity. Enhanced response was observed following 3-day, as well as 14-day, treatment and resolved within 4 days of PCP treatment withdrawal.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Effects of Mephedrone and Amphetamine Exposure During Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis
    International Journal of Molecular Sciences Article Effects of Mephedrone and Amphetamine Exposure during Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis Pawel Grochecki 1, Irena Smaga 2 , Malgorzata Lopatynska-Mazurek 1, Ewa Gibula-Tarlowska 1, Ewa Kedzierska 1, Joanna Listos 1, Sylwia Talarek 1, Marta Marszalek-Grabska 3 , Magdalena Hubalewska-Mazgaj 2, Agnieszka Korga-Plewko 4 , Jaroslaw Dudka 5, Zbigniew Marzec 6, Małgorzata Filip 2 and Jolanta H. Kotlinska 1,* 1 Department of Pharmacology and Pharmacodynamics, Medical University, 20-093 Lublin, Poland; [email protected] (P.G.); [email protected] (M.L.-M.); [email protected] (E.G.-T.); [email protected] (E.K.); [email protected] (J.L.); [email protected] (S.T.) 2 Department of Drug Addiction Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland; [email protected] (I.S.); [email protected] (M.H.-M.); mal.fi[email protected] (M.F.) 3 Department of Experimental and Clinical Pharmacology, Medical University, 20-090 Lublin, Poland; [email protected] 4 Independent Medical Biology Unit, Medical University, 20-090 Lublin, Poland; [email protected] 5 Department of Toxicology, Medical University, 20-090 Lublin, Poland; [email protected] 6 Department of Food and Nutrition, Medical University, 20-093 Lublin, Poland; [email protected] Citation: Grochecki, P.; Smaga, I.; * Correspondence: [email protected] Lopatynska-Mazurek, M.; Gibula-Tarlowska, E.; Kedzierska, E.; Abstract: A synthetic cathinone, mephedrone is widely abused by adolescents and young adults. Listos, J.; Talarek, S.; Despite its widespread use, little is known regarding its long-term effects on cognitive function.
    [Show full text]
  • Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
    208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15].
    [Show full text]
  • Stimulant and Related Medications: US Food and Drug
    Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for stimulant and related medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved dosages and indications for the use of stimulant and related medications in adults are provided in this table. All medication doses listed are for oral administration. Information on the generic availability of the stimulant and related medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Dosing Information Other Information Availability amphetamine/dextroamphetamine ADHD Initial dose: May increase daily dose by 5 mg at Yes mixed salts[1] 5 mg once or twice a day; weekly intervals until optimal response Maximum dose: 40 mg per day is achieved. Only in rare cases will it be necessary to exceed a total of 40 mg per day. amphetamine/dextroamphetamine narcolepsy Initial dose: 10 mg per day; May increase daily dose by 10 mg at Yes mixed salts Usual dose: weekly intervals until optimal response 5 mg to 60 mg per day is achieved. Take first dose in divided doses upon awakening. amphetamine/dextroamphetamine ADHD Recommended dose: Patients switching from regular-release Yes mixed salts ER*[2] 20 mg once a day amphetamine/dextroamphetamine mixed salts may take the same total daily dose once a day. armodafinil[3] narcolepsy Recommended dose: Take as a single dose in the morning.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • MDPV) (Street Names: “Bath Salts,” “Ivory Wave,” “Plant Fertilizer,” “Vanilla Sky,” “Energy-1”) December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxypyrovalerone (MDPV) (Street Names: “bath salts,” “Ivory Wave,” “plant fertilizer,” “Vanilla Sky,” “Energy-1”) December 2019 Introduction: reported for stimulants such as cocaine and methamphetamine. 3,4-Methylenedioxypyrovalerone (MDPV) is a designer MDPV has been reported to induce subjective effects in drug of the phenethylamine class. MDPV is structurally humans similar to those induced by cocaine, amphetamine, and related to cathinone, an active alkaloid found in the khat MDMA. The subjective effects induced by substituted plant, 3,4-methylenedioxymethamphetamine (MDMA), cathinones are feelings of empathy, stimulation, alertness, methamphetamine, and other schedule I phenethylamines. euphoria, and awareness of senses. Other effects reported from MDPV, like some other substances in this class, is a central the use of MDPV were tachycardia, hypertension, nervous system (CNS) stimulant. MDPV is also reported to vasoconstriction, and sweating. MDPV has also been reported have hallucinogenic effects. MDPV has been identified in to cause intense, prolonged panic attacks in users. Repeat products that are falsely marketed as “bath salts,” “plant users have reported bouts of psychosis and a craving or a strong food,” and “research chemicals” and is sold over the Internet desire or urge to use again. There have been reports of deaths and at local retail shops. in which MDPV was either implicated or ruled as the cause of death. Licit Uses: Users of MDPV anecdotally reported that they take 25 mg MDPV is not approved for medical use in the United or less per session. The duration of the subjective effects is States.
    [Show full text]
  • Pharmacy Prior Authorization Guideline 1. Criteria
    Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline Guideline Name ADHD Medications: Adderall (amphetamine-dextroamphetamine mixed salts), Adderall XR (amphetamine-dextroamphetamine mixed salts extended-release), Adzenys ER (amphetamine), Adzenys XR-ODT (amphetamine), Aptensio XR (methylphenidate), amphetamine, amphetamine-dextroamphetamine mixed salts, amphetamine-dextroamphetamine mixed salts extended-release, Concerta (methylphenidate), Cotempla-XR ODT (methylphenidate), Daytrana (methylphenidate), Desoxyn (methamphetamine), Dexedrine (dextroamphetamine), dexmethylphenidate, dexmethylphenidate extended- release, dextroamphetamine, dextroamphetamine extended-release, dextroamphetamine oral solution, Dyanavel XR (amphetamine), Evekeo (amphetamine), Focalin (dexmethylphenidate), Focalin XR (dexmethylphenidate), Jornay PM (methylphenidate), Metadate ER (methylphenidate), methamphetamine, Methylin oral solution (methylphenidate), methylphenidate, methylphenidate chewable tablets, methylphenidate extended-release, methylphenidate extended-release (CD), methylphenidate extended-release (LA), methylphenidate extended- release OSM, methylphenidate oral solution, Mydayis (amphetamine- dextroamphetamine), Procentra (dextroamphetamine), Quillivant XR (methylphenidate), Quillichew ER (methylphenidate), Relexxii (methylphenidate), Ritalin (methylphenidate), Ritalin LA (methylphenidate), Vyvanse (lisdexamfetamine), and Zenzedi (dextroamphetamine) 1. Criteria Product Name: Brand Adderall, Generic amphetamine-dextroamphetamine mixed
    [Show full text]
  • Methamphetamine Use: Lessons Learned
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Methamphetamine Use: Lessons Learned Author(s): Dana Hunt, Ph.D.; Sarah Kuck; Linda Truitt, Ph.D. Document No.: 209730 Date Received: February 2006 Award Number: 99-C-008 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. ANALYTIC SUPPORT PROGRAM CONTRACT TASK REQUIREMENT T-043: Methamphetamine Use: Lessons Learned Contract No. 99-C-008 Cambridge, MA Lexington, MA Hadley, MA Bethesda, MD Chicago, IL January 31, 2006 Prepared for Raymond C. German Contracting Officer Christine Crossland Senior Social Science Analyst National Institute of Justice Office of Justice Programs Acquisition Management Division 810 Seventh Street, SW Washington, D.C. 20001 Prepared by Dana Hunt, Ph.D. Sarah Kuck Abt Associates Inc. Linda Truitt, Ph.D. 55 Wheeler Street Cambridge, MA 02138 Contents Executive Summary...............................................................................................................iii History of Methamphetamine Use .................................................................................iii Trends.............................................................................................................................iii
    [Show full text]
  • Scientific Article
    PEDIATRIC DENTISTRY V 29 / NO 6 NOV / DEC 07 Scientifi c Article Pharmacologic Behavior Management of Pediatric Dental Patients Diagnosed with AttentionAttention DDefiefi ccitit DisDisorder/Attentionorder/Attention DDefiefi ccitit HHyperactivityyperactivity DisDisorderorder Carolyn A. Kerins, DDS, PhD1 • Alton G. McWhorter, DDS, MS2 • N. Sue Seale, DDS, MSD3 Abstract: Purpose: The purpose of this study was to conduct a survey of Texas pediatric dentists to determine: (1) the percentage of patients they treat with attention defi cit disorder (ADD)/attention defi cit hyperactivity disorder (ADHD); (2) the behavior management techniques that are utilized to treat their patients who suffer from ADD/ADHD; and (3) the relative success rates of these techniques in their practices. Methods: A 17-question, single-answer, multiple choice survey was mailed to 343 Texas pediatric dentists. The mailing list was obtained from American Academy of Pediatric Dentistry and Texas Academy of Pediatric Dentistry member rosters. One mailing was sent, including a self-addressed stamped envelope, for returned responses. Results: A 54% response rate (186 surveys) revealed that nitrous oxide was the most frequently used pharmacologic behavior management technique; however, demerol/promethazine/nitrous oxide was rated as effective most often for treat- ing ADD/ADHD patients. Conclusions: Practitioners believe the incidence of attention defi cit disorder/attention defi cit hyperactivity disorder is increasing, and they are familiar with the medications used to treat the conditions. Texas pediatric dentists are using a variety of sedation techniques and are interested in developing guidelines for sedation of these patients. (Pediatr Dent 2007;29:507-13) Received July 20, 2006 / Revision Accepted FebruaryFebruary 66,, 2002007.7.
    [Show full text]
  • MEDICATION GUIDE Adderall (ADD-Ur-All) (CII
    MEDICATION GUIDE Adderall® (ADD-ur-all) (CII) (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) Read the Medication Guide that comes with Adderall® before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your child’s treatment with Adderall® . What is the most important information I should know about Adderall® ? The following have been reported with use of Adderall® and other stimulant medicines. 1. Heart-Related Problems: • sudden death in patients who have heart problems or heart defects • stroke and heart attack in adults • increased blood pressure and heart rate Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. Your doctor should check you or your child carefully for heart problems before starting Adderall® . Your doctor should check your or your child’s blood pressure and heart rate regularly during treatment with Adderall® . Call your doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Adderall® . 2. Mental (Psychiatric) Problems: All Patients • new or worse behavior and thought problems • new or worse bipolar illness • new or worse aggressive behavior or hostility Children and Teenagers • new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.
    [Show full text]